A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 112 participants.
Also called NCT07311551
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 112 participants
- Sponsor
- Bhavya Bhavya, MD
- Registry
-
NCT07311551
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07311551. Randomized; no masking; primary purpose treatment. Start 2025-12-24 (anticipated); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Dapagliflozin (10Mg Tab) along with standard medical therapy
- Intervention (Drug)
- Empagliflozin (25 Mg Tab) along with standard medical therapy
- Lead sponsor
- Bhavya Bhavya, MD
Record details
- Record id
cardio:ct-nct07311551- Content hash
1a3782daffe47698a2f6ca1dc63f196c2a2fdfe5bb786edfefffc0fffcf5fcb4